Lipoamino acids as major components of absorption promoters in drug delivery

Current Topics in Medicinal Chemistry

Volumn 12, Issue 14, 2012, Pages 1562-1580

  Ziora, Zyta M ^a   Blaskovich, Mark A ^a   Toth, Istvan ^a   Cooper, Matthew A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Absorption promoter; Dendrimers; Drug bioavailability; Drug delivery; Ion pairing agents; Lipoamino acids; Penetration enhancers

Indexed keywords

ALPHA AMINO ACID; CELECOXIB; DENDRIMER; DEXTRAN SULFATE; GENTAMICIN; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; GLYCOLIPID; LAURIC ACID; LIPID; LIPOAMINO ACID; LIPOPEPTIDE; LOW MOLECULAR WEIGHT HEPARIN; MEDIUM CHAIN TRIACYLGLYCEROL; MYRISTIC ACID; NANOCARRIER; PALMITIC ACID; PENETRATION ENHANCING AGENT; PENICILLIN G; PHOSPHATIDYLCHOLINE; PIPERACILLIN; POLYELECTROLYTE; POLYLYSINE; POLYMER LIPID HYBRID NANOPARTICLE; SOLID LIPID NANOPARTICLE; STEARIC ACID; SURFACTANT; TRISTEARIN; TRITON X 100; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADSORPTION; CHEMICAL MODIFICATION; CRITICAL MICELLE CONCENTRATION; DIFFUSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG UPTAKE; ENCAPSULATION; HYDROPHILICITY; LIPOPHILICITY; LYMPHATIC SYSTEM; MEMBRANE PERMEABILITY; NANOTECHNOLOGY; NONHUMAN; REVIEW; SLOW DRUG RELEASE;

ABSORPTION; AMINO ACIDS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS;

EID: 84866932008     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612802652448     Document Type: Review

References (170)

1. Wong, A.; Toth, I., Lipid, sugar and liposaccharide based delivery systems. Curr. Med. Chem., 2001, 8(9), 1123-1136.
2. Toth, I.; Flinn, N.; Hillery, A.; Gibbons, W.A.; Artursson, P., Lipidic conjugates of luteinizing-hormone-releasing hormone (LHRH)+ and thyrotropin-releasing-hormone (TRH)+ that release and protect the native hormones in homogenates of humane intestinal epithelial (CACO-2) cells. Int. J. Pharm., 1994, 105(3), 241-247.
3. Nadolski, M.J.; Linder, M.E., Protein lipidation. FEBS J., 2007, 274(20), 5202-5210.
4. Chua, B.Y.; Healy, A.; Cameron, P.U.; Stock, O.; Rizkalla, M.; Zeng, W.G.; Torresi, J.; Brown, L.E.; Fowler, N.L.; Gowans, E.J.; Jackson, D.C., Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol. Cell Biol., 2003, 81(1), 67-72.
5. Chua, B.Y.; Eriksson, E.M.; Brown, L.E.; Zeng, W.G.; Gowans, E.J.; Torresi, J.; Jackson, D.C., A self-adjuvanting lipopeptidebased vaccine candidate for the treatment of hepatitis C virus infection. Vaccine, 2008, 26(37), 4866-4875.
6. Phillipps, K.S.M.; Wykes, M.N.; Liu, X.Q.; Brown, M.; Blanchfield, J.; Toth, I., A novel synthetic adjuvant enhances dendritic cell function. Immunology, 2009, 128(1), e582-e588.
7. Skwarczynski, M.; Hayashi, Y.; Kiso, Y., Paclitaxel prodrugs: Toward smarter delivery of anticancer agents. J. Med. Chem., 2006, 49(25), 7253-7269.
8. Blanchfield, J.; Toth, I., Lipid, sugar and liposaccharide based delivery systems 2. Curr. Med. Chem., 2004, 11(17), 2375-2382.
9. Hughes, R.A.; Toth, I.; Ward, P.; Ireland, S.J.; Gibbons, W.A., Lipidic peptides.3. Lipidic amino-acids and oligomer conjugates of morphine. J. Pharm. Sci., 1991, 80(12), 1103-1105.
10. Toth, I.; Hughes, R.A.; Ward, P.; Baldwin, M.A.; Welham, K.J.; McColm, A.M.; Cox, D.M.; Gibbons, W.A., Lipidic peptides.4. Penicillin and cephalosporin amide conjugates with lipidic aminoacids and their oligomers. Int. J. Pharm., 1991, 73(3), 259-266.
11. Kellam, B.; Drouillat, B.; Dekany, G.; Starr, M.S.; Toth, I., Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents. Int. J. Pharm., 1998, 161(1), 55-64.
12. Lee, V.H.L.; Yamamoto, A.; Kompella, U.B., Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst., 1991, 8(2), 91-192.
13. QuintanarGuerrero, D.; Allemann, E.; Fessi, H.; Doelker, E., Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides. Pharm. Res., 1997, 14(2), 119-127.
14. Kawakami, K.; Yoshikawa, T.; Hayashi, T.; Nishihara, Y.; Masuda, K., Microemulsion formulation for enhanced absorption of poorly soluble drugs-II. In vivo study. J. Controlled Release, 2002, 81(1-2), 75-82.
15. Toth, I., A novel chemical approach to drug-delivery-lipidic amino-acid conjugates. J. Drug Targeting, 1994, 2(3), 217-239.
16. Wilke, D.V.; Jimenez, P.C.; Araujo, R.M.; Barbosa da Silva, W.M.; Loiola Pessoa, O.D.; Silveira, E.R.; Pessoa, C.; de Moraes, M.O.; Skwarczynski, M.; Simerska, P.; Toth, I.; Costa-Lotufo, L.V., Pro-apoptotic activity of lipidic alpha-amino acids isolated from Protopalythoa variabilis. Bioorg. Med. Chem., 2010, 18(22), 7997-8004.
17. Duncan, S.J.; Gruschow, S.; Williams, D.H.; McNicholas, C.; Purewal, R.; Hajek, M.; Gerlitz, M.; Martin, S.; Wrigley, S.K.; Moore, M., Isolation and structure elucidation of chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc., 2001, 123(4), 554-560.
18. Shiba, T.; Mukunoki, Y.; Akiyama, H., Component amino-acids of antibiotic longicatenamycin-isolation of 5-chloro-d-tryptophan. Bull. Chem. Soc. Jpn., 1975, 48(6), 1902-1906.
19. Kluepfel, D.; Vezina, C.; Sehgal, S.N.; Kudelski, A.; Charest, M.P.; Bagli, J., Myriocin, a new antifungal antibiotic from myriococcum-albomyces. J. Antibiot., 1972, 25(2), 109-&.
20. Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Yoneta, M.; Chiba, K.; Hoshino, Y.; Okumoto, T., Fungal metabolites.12. potent immunosuppressant, 14-deoxomyriocin, (2s, 3r, 4r)-(e)-2-amino-3, 4-dihydroxy-2-hydroxymethyleicos-6-enoic acid and structure-activityrelationships of myriocin derivatives. J. Antibiot., 1994, 47(2), 216-224.
21. Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y.; Okumoto, T., Fungal metabolites.11. a potent immunosuppressive activity found in isaria-sinclairii metabolite. J. Antibiot., 1994, 47(2), 208-215.
22. Horn, W.S.; Smith, J.L.; Bills, G.F.; Raghoobar, S.L.; Helms, G.L.; Kurtz, M.B.; Marrinan, J.A.; Frommer, B.R.; Thornton, R.A.; Mandala, S.M., Sphingofungin-E and sphingofungin-F-novel serinepalmitoyl transferase inhibitors from paecilomyces-variotii. J. Antibiot., 1992, 45(10), 1692-1696.
23. Vanmiddlesworth, F.; Dufresne, C.; Wincott, F.E.; Mosley, R.T.; Wilson, K.E., Determination of the relative and absolute stereochemistry of sphingofungin-A, sphingofungin-B, sphingofungin-C, and sphingofungin-D. Tetrahedron Lett., 1992, 33(3), 297-300.
24. Vanmiddlesworth, F.; Giacobbe, R.A.; Lopez, M.; Garrity, G.; Bland, J.A.; Bartizal, K.; Fromtling, R.A.; Polishook, J.; Zweerink, M.; Edison, A.M.; Rozdilsky, W.; Wilson, K.E.; Monaghan, R.L., Sphingofungin-A, sphingofungin-B, sphingofungin-C, and sphingofungin-D-a new family of antifungal agents.1. fermentation, isolation, and biological-activity. J. Antibiot., 1992, 45(6), 861-867.
25. Waldmann, H.; Schelhaas, M.; Nagele, E.; Kuhlmann, J.; Wittinghofer, A.; Schroeder, H.; Silvius, J.R., Chemoenzymatic synthesis of fluorescent N-ras lipopeptides and their use in membrane localization studies in vivo. Angew. Chem., Int. Ed., 1997, 36(20), 2238-2241.
26. Cotte, A.; Bader, B.; Kuhlmann, J.; Waldmann, H., Synthesis of the N-terminal lipohexapeptide of human GαO-protein and fluorescent-labeled analogs for biological studies. Chem.--Eur. J., 1999, 5, 922-936.
27. Walsh, C.T.; Garneau-Tsodikova, S.; Gatto, G.J., Jr., Protein posttranslational modifications: The chemistry of proteome diversifications. Angew. Chem., Int. Ed., 2005, 44, 7342-7372.
28. Ousanova, M.P.; Sebyakin, Y.L., The structure, synthesis, and immunomodulating activity of bacterial lipopeptides and their analogues. Russ. Chem. Rev., 1997, 66(10), 889-900.
29. Marvel, C.S.; Noyes, W.A., A study of the possible asymmetry of the aliphatic diazo compounds. J. Am. Chem. Soc., 1920, 42, 2259-2278.
30. Parnaud, J.J.; Campari, G.; Pino, P., Some aspects of the catalytic synthesis of n-acyl-alpha-aminoacids by carbonylation of aldehydes in the presence of amides. J. Mol. Catal., 1979, 6(5), 341-350.
31. Beller, M.; Eckert, M.; Moradi, W.A., First amidocarbonylation with nitriles for the synthesis of N-acyl amino acids. Synlett, 1999(1), 108-110.
32. Gerencev N; Castek, A.; Sateva, M.; Pluscec, J.; Prosteni. M, Preparation of alpha-arylamidoketones from alpha-amino acids. Monatshefte Fur Chemie Und Verwandte Teile Anderer Wissenschaften, 1966, 97(2), 331-&.
33. Greenstein, J.P.; Winitz, N. Chemistry of the Amino Acids. Wiley: New York, NY, pp 2381-2406, 1961.
34. Kimura, Y., Studies on acylase activity and microorganisms.21. Optical resolution of higher amino acids by acylase of soil bacteria. Chem. Pharm. Bull., 1962, 10(12), 1154-1157.
35. Albanese, D.; Landini, D.; Penso, M., Synthesis of 2-amino acids via selective mono-N-alkylation of trichloroacetamide by 2-bromo carboxylic esters under solid-liquid phase-transfer catalysis conditions. J. Org. Chem., 1992, 57, 1603-1605.
36. Birnbaum, S.M.; Fu, S.C.J.; Greenstein, J.P., Resolution of the racemic alpha-amino derivatives of heptylic, caprylic, nonylic, decylic, and undecylic acids. J. Biol. Chem., 1953, 203(1), 333-338.
37. Landini, D.; Penso, M., N-alkylation of trifluoroacetamide with 2-bromo carboxylic esters under PTC conditions: a new procedure for the synthesis of α-amino acids. J. Org. Chem., 1991, 56, 420-423.
38. Albertson, N.F., The synthesis of amino acids from ethyl acetamidomalonate and ethyl acetamidocyanoacetate.3. The use of primary halides. J. Am. Chem. Soc., 1946, 68(3), 450-453.
39. Gibbons, W.A.; Hughes, R.A.; Charalambous, M.; Christodoulou, M.; Szeto, A.; Aulabaugh, A.E.; Mascagni, P.; Toth, I., Lipidic peptides.1. Synthesis, resolution and structural elucidation of lipidic amino-acids and their homo-oligomers and heterooligomers Liebigs Ann. Chem., 1990(12), 1175-1183.
40. Stork, G.; Leong, A.Y.W.; Touzin, A.M., Alkylation and Michael additions of glycine ethyl ester. Use in α-amino acid synthesis and as acyl carbanion equivalent. J. Org. Chem., 1976, 41, 3491-3493.
41. Tzalis, D.; Knochel, P., Ru-centered coordination complexes as a new phase transfer catalyst for alkylation of enolates and Michael additions. Tetrahedron Lett., 1999, 40, 3685-3688.
42. Ghosez, L.; Antoine, J.P.; Deffense, E.; Navarro, M.; Libert, V.; O'Donnell, M.J.; Bruder, W.A.; Willey, K.; Wojciechowski, K., Synthesis of amino acids. Alkylation of aldimine and ketimine derivatives of glycine ethyl ester under various phase-transfer conditions. Tetrahedron Lett., 1982, 23, 4255-4258.
43. O'Donnell, M.J.; Lugar, C.W.; Pottorf, R.S.; Zhou, C.; Scott, W.L.; Cwi, C.L., Solid-phase synthesis of unnatural amino acids using unactivated alkyl halides. Tetrahedron Lett., 1997, 38, 7163-7166.
44. Park, H.-G.; Kim, M.-J.; Park, M.-K.; Jung, H.-J.; Lee, J.; Lee, Y.-J.; Jeong, B.-S.; Lee, J.-H.; Yoo, M.-S.; Ku, J.-M.; Jew, S.-s., Solid-phase synthetic method for (±)-α-amino acids via phasetransfer catalytic alkylation. Tetrahedron Lett., 2005, 46, 93-95.
45. Marshall, J.A.; Garofalo, A.W., Oxidative cleavage of mono-, di-, and trisubstituted olefins to methyl esters through ozonolysis in methanolic sodium hydroxide. J. Org. Chem., 1993, 58, 3675-3680.
46. Miyazawa, T.; Iwanaga, H.; Ueji, S.; Yamada, T.; Kuwata, S., Porcine pancreatic lipase catalyzed enantioselective hydrolysis of esters of N-protected unusual amino acids. Chem. Lett., 1989, 2219-2222.
47. Chen, Y.; Bilban, M.; Foster, C.A.; Boger, D.L., Solution-Phase Parallel Synthesis of a Pharmacophore Library of HUN-7293 Analogues: A General Chemical Mutagenesis Approach To Defining Structure-Function Properties of Naturally Occurring Cyclic Depsipeptides. J. Am. Chem. Soc., 2002, 124, 5431-5440.
48. Goudreau, N.; Brochu, C.; Cameron, D.R.; Duceppe, J.-S.; Faucher, A.-M.; Ferland, J.-M.; Grand-Maitre, C.; Poirier, M.; Simoneau, B.; Tsantrizos, Y.S., Potent Inhibitors of the Hepatitis C Virus NS3 Protease: Design and Synthesis of Macrocyclic Substrate-Based β-Strand Mimics. J. Org. Chem., 2004, 69, 6185-6201.
49. Kokotos, G.; Padron, J.M.; Noula, C.; Gibbons, W.A.; Martin, V.S., A general approach to the enantiomeric synthesis of lipidic α-amino acids, peptides and vicinal amino alcohols. Tetrahedron-Asymmetry, 1996, 7, 857-866.
50. Lee, J.; Choi, W.-B.; Lynch, J.E.; Volante, R.P.; Reider, P.J., Practical synthesis of α-amino acids using cis-aminoindanol derived hippuric acid amide as a glycine enolate equivalent. Tetrahedron Lett., 1998, 39, 3679-3682.
51. Schoellkopf, U.; Neubauer, H.J., Asymmetric syntheses via heterocyclic intermediates. XII. Enantioselective synthesis of (R)-α-amino acids using tert-leucine as chiral auxiliary reagent. Synthesis, 1982, 861-864.
52. Papini, A.M.; Nardi, E.; Nuti, F.; Uziel, J.; Ginanneschi, M.; Chelli, M.; Brandi, A., Diastereoselective alkylation of Schiff bases for the synthesis of lipidic unnatural Fmoc-protected α-amino acids. Eur. J. Org. Chem., 2002, 2736-2741.
53. Schuda, P.F.; Greenlee, W.J.; Chakravarty, P.K.; Eskola, P., A short and efficient synthesis of (3S, 4S)-4-[(tert-Butyloxycarbonyl)amino]-5-cyclohexyl-3-hydroxypentanoic acid ethyl ester. J. Org. Chem., 1988, 53, 873-875.
54. O'Donnell, M.J.; Delgado, F.; Pottorf, R.S., Enantioselective solidphase synthesis of α-amino acid derivatives. Tetrahedron, 1999, 55, 6347-6362.
55. O'Donnell, M.J.; Delgado, F.; Hostettler, C.; Schwesinger, R., An efficient homogeneous catalytic enantioselective synthesis of α-amino acid derivatives. Tetrahedron Lett., 1998, 39, 8775-8778.
56. Park, H.-g.; Kim, M.-J.; Park, M.-K.; Jung, H.-J.; Lee, J.; Choi, S.-h.; Lee, Y.-J.; Jeong, B.-S.; Lee, J.-H.; Yoo, M.-S.; Ku, J.-M.; Jew, S.-S., Highly Enantioselective Phase-Transfer Catalytic Alkylation in the Preparation of Non-natural α-Amino Acids via Solid Phase Synthesis Using Aldimine Linker. J. Org. Chem., 2005, 70, 1904-1906.
57. Yu, H.; Takigawa, S.; Koshima, H., Asymmetric alkylation of glycine imine esters using solid supports preloaded with base. Tetrahedron, 2004, 60, 8405-8410.
58. Kumar, S.; Ramachandran, U., Cinchona alkaloid phase-transfer catalysts revisited: influence of substituted aryl groups on the enantioselectivity of glycine ester enolate alkylation. Tetrahedron, 2005, 61, 7022-7028.
59. Kita, T.; Georgieva, A.; Hashimoto, Y.; Nakata, T.; Nagasawa, K., C2-symmetric chiral pentacyclic guanidine: A phase-transfer catalyst for the asymmetric alkylation of tert-butyl glycinate Schiff base. Angew. Chem., Int. Ed., 2002, 2832-2834.
60. Park, H.-g.; Jeong, B.-S.; Yoo, M.-S.; Lee, J.-H.; Park, B.-s.; Kim, M.G.; Jew, S.-s., Highly efficient ortho-fluoro-dimeric cinchonaderived phase-transfer catalysts. Tetrahedron Lett., 2003, 44, 3497-3500.
61. Bajgrowicz, J.A.; El Hallaoui, A.; Jacquier, R.; Pigiere, C.; Viallefont, P., Lithium diorganocuprate reactions with l-serine derivatives. Tetrahedron Lett., 1984, 25(26.), 2759-2762.
62. Bajgrowicz, J.A.; El, H.A.; Jacquier, R.; Pigiere, C.; Viallefont, P., Organocuprates in a novel synthesis of optically pure amino acids. Tetrahedron, 1985, 41, 1833-1843.
63. Bernardini, A.; El, H.A.; Jacquier, R.; Pigiere, C.; Viallefont, P.; Bajgrowicz, J., Use of organocuprates in amino acid synthesis. Tetrahedron Lett., 1983, 24, 3717-3720.
64. Rodriguez, A.; Miller, D.D.; Jackson, R.F.W., Combined application of organozinc chemistry and one-pot hydroboration-Suzuki coupling to the synthesis of amino acids. Org. Biomol. Chem., 2003, 1, 973-977.
65. Padron, J.M.; Kokotos, G.; Martin, T.; Markidis, T.; Gibbons, W.A.; Martin, V.S., Enantiospecific synthesis of α-amino acid semialdehydes: a key step for the synthesis of unnatural unsaturated and saturated α-amino acids. Tetrahedron-Asymmetry, 1998, 9, 3381-3394.
66. Kokotos, G.; Padron, J.M.; Martin, T.; Gibbons, W.A.; Martin, V.S., A General Approach to the Asymmetric Synthesis of Unsaturated Lipidic α-Amino Acids. The First Synthesis of α-Aminoarachidonic Acid. J. Org. Chem., 1998, 63, 3741-3744.
67. Burk, M.J.; Bedingfield, K.M.; Kiesman, W.F.; Allen, J.G., Catalytic asymmetric hydrogenation of β-substituted α, β, γ, δ-unsaturated amino acids. Tetrahedron Lett., 1999, 40, 3093-3096.
68. Burk, M.J.; Allen, J.G.; Kiesman, W.F., Highly Regio-and Enantioselective Catalytic Hydrogenation of Enamides in Conjugated Diene Systems: Synthesis and Application of γ, δ-Unsaturated Amino Acids. J. Am. Chem. Soc., 1998, 120, 657-663.
69. Burk, M.J.; Feaster, J.E.; Nugent, W.A.; Harlow, R.L., Preparation and use of C2-symmetric bis(phospholanes): production of α-amino acid derivatives via highly enantioselective hydrogenation reactions. J. Am. Chem. Soc., 1993, 115, 10125-10138.
70. Biagini, S.C.G.; Gibson, S.E.; Keen, S.P., Cross-metathesis of unsaturated α-amino acid derivatives. J. Chem. Soc., Perkin Trans. 1, 1998, 2485-2500.
71. Gibson, S.E.; Gibson, V.C.; Keen, S.P., Cross metathesis of the amino acid homoallylglycine. Chem. Commun. (Cambridge), 1997, 1107-1108.
72. Aungst, B.J., Intestinal permeation enhancers. J. Pharm. Sci., 2000, 89(4), 429-442.
73. Toth, I.; Danton, M.; Flinn, N.; Gibbons, W.A., A combined adjuvant and carrier system for enhancing synthetic peptides immunogenicity utilizing lipidic amino-acids. Tetrahedron Lett., 1993, 34(24), 3925-3928.
74. Patri, A.K.; Simanek, E., Biological Applications of Dendrimers. Mol. Pharm., 2012, 9(3), 341-341.
75. Koda, Y.; Del Borgo, M.; Wessling, S.T.; Lazarus, L.H.; Okada, Y.; Toth, I.; Blanchfield, J.T., Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg. Med. Chem., 2008, 16(11), 6286-6296.
76. Koda, Y.; Liang, M.T.; Blanchfield, J.T.; Toth, I., In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue. Int. J. Pharm., 2008, 356(1-2), 37-43.
77. Zhong, W.; Skwarczynski, M.; Toth, I., Lipid Core Peptide System for Gene, Drug, and Vaccine Delivery. Aust. J. Chem., 2009, 62(9), 956-967.
78. Purohit, G.; Sakthivel, T.; Florence, A.T., The interaction of cationic dendrons with albumin and their diffusion through cellulose membranes. Int. J. Pharm., 2003, 254(1), 37-41.
79. Purohit, G.; Sakthivel, T.; Florence, A.T., Interaction of cationic partial dendrimers with charged and neutral liposomes. Int. J. Pharm., 2001, 214(1-2), 71-76.
80. Sakthivel, T.; Florence, A.T., Adsorption of amphipathic dendrons on polystyrene nanoparticles. Int. J. Pharm., 2003, 254(1), 23-26.
81. Zloh, M.; Ramaswamy, C.; Sakthivel, T.; Wilderspin, A.; Florence, A.T., Investigation of the association and flexibility of cationic lipidic peptide dendrons by NMR spectroscopy. Magn. Reson. Chem., 2005, 43(1), 47-52.
82. Sakthivel, T.; Toth, I.; Florence, A.T., Synthesis and physicochemical properties of lipophilic polyamide dendrimers. Pharm. Res., 1998, 15(5), 776-782.
83. Morikawa, A.; Kakimoto, M.; Imai, Y., Synthesis and characterization of new polysiloxane starburst polymers Macromolecules, 1991, 24(12), 3469-3474.
84. Zhang, J.S.; Moore, J.S.; Xu, Z.F.; Aguirre, R.A., Nanoarchitectures.1. Controlled synthesis of phenylacetylene sequences J. Am. Chem. Soc., 1992, 114(6), 2273-2274.
85. Sakthivel, T.; Toth, I.; Florence, A.T., Distribution of a lipidic 2.5 nm diameter dendrimer carrier after oral administration. Int. J. Pharm., 1999, 183(1), 51-55.
86. Florence, A.T.; Sakthivel, T.; Toth, I., Oral uptake and translocation of a polylysine dendrimer with a lipid surface. J. Controlled Release, 2000, 65(1-2), 253-259.
87. Al-Jamal, K.T.; Sakthivel, T.; Florence, A.T., Dendrisomes: cationic lipidic dendron vesicular assemblies. Int. J. Pharm., 2003, 254(1), 33-36.
88. Al-Jamal, K.T.; Sakthivel, T.; Florence, A.T., Solubilisation and transformation of amphipathic lipidic dendron vesicles (dendrisomes) into mixed micelles. Colloids and Surfaces a-Physicochemical and Engineering Aspects, 2005, 268(1-3), 52-59.
89. Bayele, H.K.; Ramaswamy, C.; Wilderspin, A.F.; Srai, K.S.; Toth, I.; Florence, A.T., Protein transduction by lipidic peptide dendrimers. J. Pharm. Sci., 2006, 95(6), 1227-1237.
90. Yanai, S.; Sakthivel, T.; Florence, A.T., Interfacial behaviour and micelle formation of novel amphiphilic sequential lipid-lysine oligomers. Int. J. Pharm., 2001, 214(1-2), 49-53.
91. Al-Jamal, K.T.; Ramaswamy, C.; Florence, A.T., Supramolecular structures from dendrons and dendrimers. Adv. Drug Delivery Rev., 2005, 57(15), 2238-2270.
92. Gabius, H.J., The sugar code in drug delivery. Adv. Drug Delivery Rev., 2004, 56(4), 421-424.
93. Turnbull, W.B.; Stoddart, J.F., Design and synthesis of glycodendrimers. J. Biotechnol., 2002, 90(3-4), 231-255.
94. Roy, R.; Baek, M.-G., Glycodendrimers: novel glycotope isosteres unmasking sugar coding. case study with T-antigen markers from breast cancer MUC1 glycoprotein. J. Biotechnol., 2002, 90(3-4), 291-309.
95. Lahmann, M. In Glycoscience and Microbial Adhesion. Lindhorst, T.K.O.S., Ed., 2009; 288, 17-65.
96. Zhang, H.; Ma, Y.; Sun, X.-L., Recent Developments in Carbohydrate-Decorated Targeted Drug/Gene Delivery. Med. Res. Rev., 2010, 30(2), 270-289.
97. Drouillat, B.; Hillery, A.M.; Dekany, G.; Falconer, R.; Wright, K.; Toth, I., Novel liposaccharide conjugates for drug and peptide delivery. J. Pharm. Sci., 1998, 87(1), 25-30.
98. McGeary, R.P.; Jablonkai, I.; Toth, I., Carbohydrate-based templates for synthetic vaccines and drug delivery. Tetrahedron, 2001, 57(41), 8733-8742.
99. Gyorgydeak, Z.; Szilagyi, L.; Paulsen, H., Synthesis, structure and reactions of glycosyl azides. J. Carbohydr. Chem., 1993, 12(2), 139-163.
100. Hayes, P.Y.; Ross, B.P.; Thomas, B.G.; Toth, I., Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin. Bioorg. Med. Chem., 2006, 14(1), 143-152.
101. Toth, I.; Anderson, G.J.; Hussain, R.; Wood, I.P.; Fernandez, E.D.; Ward, P.; Gibbons, W.A., Lipidic Peptides.10. Synthesis, structural and physico-chemical elucidation of lipidic amino acid conjugates with hydrophilic compounds Tetrahedron, 1992, 48(5), 923-930.
102. Ross, B.P.; DeCruz, S.E.; Lynch, T.B.; Davis-Goff, K.; Toth, I., Design, synthesis, and evaluation of a liposaccharide drug delivery agent: Application to the gastrointestinal absorption of gentamicin. J. Med. Chem., 2004, 47(5), 1251-1258.
103. Bowe, C.L.; Mokhtarzadeh, L.; Venkatesan, P.; Babu, S.; Axelrod, H.R.; Sofia, M.J.; Kakarla, R.; Chan, T.Y.; Kim, J.S.; Lee, H.J.; Amidon, G.L.; Choe, S.Y.; Walker, S.; Kahne, D., Design of compounds that increase the absorption of polar molecules. Proc. Natl. Acad. Sci. USA, 1997, 94(22), 12218-12223.
104. Ross, B.P.; Braddy, A.C.; McGeary, R.P.; Blanchfield, J.T.; Prokai, L.; Toth, I., Micellar aggregation and membrane partitioning of bile salts, fatty acids, sodium dodecyl sulfate, and sugar-conjugated fatty acids: Correlation with hemolytic potency and implications for drug delivery. Mol. Pharm., 2004, 1(3), 233-245.
105. Abdelrahim, A.S.; Simerska, P.; Toth, I., Development and characterization of anionic liposaccharides for enhanced oral drug delivery. Int. J. Pharm. (Amsterdam, Neth.), 2012, 430, 120-128.
106. Abdelrahim, A.S.; Ziora, Z.M.; Bergeon, J.A.; Moss, A.R.; Toth, I., Design and synthesis of a series of novel, cationic liposaccharide derivatives as potential penetration enhancers for oral drug delivery. Tetrahedron, 2009, 65(45), 9436-9442.
107. Falconer, R.A.; Toth, I., Design, synthesis and biological evaluation of novel lipoamino acid-based glycolipids for oral drug delivery. Bioorg. Med. Chem., 2007, 15(22), 7012-7020.
108. Compain, P.; Martin, O.R., Carbohydrate mimetics-based glycosyltransferase inhibitors. Bioorg. Med. Chem., 2001, 9(12), 3077-3092.
109. Ziora, Z.M.; Wimmer, N.; New, R.; Skwarczynski, M.; Toth, I., Lipopeptides for the fragment-based pharmaceutics design. Int. J. Org. Chem., 2012, 1(2), 75-81.
110. Ziora, Z.M.; Wimmer, N.; New, R.; Skwarczynski, M.; Toth, I., Synthesis of glycolipopeptidic building blocks for carbohydrate receptor discovery. Carbohydr. Res., 2011, 346(12), 1439-1444.
111. Skwarczynski, M.; Ziora, Z.M.; Coles, D.J.; Lin, I.C.; Toth, I., Thymine, adenine and lipoamino acid based gene delivery systems. Chem. Commun. (Cambridge, U. K.), 2010, 46(18), 3140-3142.
112. Thompson, C.; Cheng, W.P.; Gadad, P.; Skene, K.; Smith, M.; Smith, G.; McKinnon, A.; Knott, R., Uptake and Transport of Novel Amphiphilic Polyelectrolyte-Insulin Nanocomplexes by Caco-2 Cells-Towards Oral Insulin. Pharm. Res., 2011, 28(4), 886-896.
113. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Wu, X.Y., Development of solid lipid nanoparticles containing lonically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci., 2004, 93(8), 1993-2008.
114. Luo, Y.; Chen, D.; Ren, L.; Zhao, X.; Qin, J., Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Controlled Release, 2006, 114(1), 53-59.
115. Wong, H.L.; Rauth, A.M.; Bendayan, R.; Manias, J.L.; Ramaswamy, M.; Liu, Z.; Erhan, S.Z.; Wu, X.Y., A new polymerlipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res., 2006, 23(7), 1574-1585.
116. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Xue, H.Y.; Babakhanian, K.; Wu, X.Y., A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther., 2006, 317(3), 1372-1381.
117. Wong, H.L.; Rauth, A.M.; Bendayan, R.; Wu, X.Y., In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur. J. Pharmaceut. Biopharmaceut., 2007, 65(3), 300-308.
118. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Wu, X.Y., Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new Polymer-Lipid Hybrid Nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Controlled Release, 2006, 116(3), 275-284.
119. Li, Y.; Wong, H.L.; Shuhendler, A.J.; Rauth, A.M.; Wu, M.Y., Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J. Controlled Release, 2008, 128(1), 60-70.
120. Tan, A.; Simovic, S.; Davey, A.K.; Rades, T.; Prestidge, C.A., Silica-lipid hybrid (SLH) microcapsules: A novel oral delivery system for poorly soluble drugs. J. Controlled Release, 2009, 134(1), 62-70.
121. Kell, D.B.; Dobson, P.D.; Oliver, S.G., Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discov. Today, 2011, 16(15-16), 704-714.
122. Di, L.; Artursson, P.; Avdeef, A.; Ecker, G.F.; Faller, B.; Fischer, H.; Brian, H.J.; Kansy, M.; Kerns, E.H.; Kramer, S.D.; Lennernas, H.; Sugano, K., Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Drug Discov. Today, 2012, http://dx.doi.org/10.1016/j.drudis.2012.03.015.
123. Lowe, D., In the Pipeline. http://pipeline.corante.com/ archives/2012/04/27/how_do_drugs_get_into_cells_a_vicious_ debate.php, 2012.
124. Gomez-Orellana, I., Strategies to improve oral drug bioavailability. Expert opinion on drug delivery, 2005, 2(3), 419-433.
125. Garzonaburbeh, A.; Poupaert, J.H.; Claesen, M.; Dumont, P.; Atassi, G., 1, 3-Dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable anti-neoplastic agent. J. Med. Chem., 1983, 26(8), 1200-1203.
126. Porter, C.J.H., Drug delivery to the lymphatic system. Crit. Rev. Ther. Drug Carrier Syst., 1997, 14(4), 333-393.
127. Boyd, B.J.; Khoo, S.-M.; Whittaker, D.V.; Davey, G.; Porter, C.J.H., A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. Int. J. Pharm., 2007, 340(1-2), 52-60.
128. Mrestani, Y.; Bretschneider, B.; Hartl, A.; Neubert, R.H.H., Invitro and in-vivo studies of cefpirom using bile salts as absorption enhancers. J. Pharm. Pharmacol., 2003, 55(12), 1601-1606.
129. Mrestani, Y.; Bretschneider, B.; Hartl, A.; Brandsch, M.; Neubert, R.H.H., Influence of enhancers on the absorption and on the pharmacokinetics of cefodizime using in-vitro and in-vivo models. J. Pharm. Pharmacol., 2004, 56(4), 485-493.
130. Mrestani, Y.; Mrestani-Klaus, C.; Bretschneider, B.; Neubert, R.H.H., Improvement of lipophilicity and membrane transport of cefuroxime using in vitro models. Eur. J. Pharmaceut. Biopharmaceut., 2004, 58(3), 653-657.
131. Mrestani, Y.; Hartl, A.; Neubert, R.H.H., Influence of absorption enhancers on the pharmacokinetic properties of non-oral betalactam-cefpirom using the rabbit (Chinchilla) in vivo model. Int. J. Pharm., 2006, 309(1-2), 67-70.
132. Jain, V.; Prasad, V.; Jadhav, P.; Mishra, P.R., Preparation and performance evaluation of saquinavir laden cationic submicron emulsions. Drug Delivery, 2009, 16(1), 37-44.
133. Miller, J.M.; Dahan, A.; Gupta, D.; Varghese, S.; Amidon, G.L., Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J. Controlled Release, 2009, 137(1), 31-37.
134. Miyake, M.; Minami, T.; Oka, Y.; Kamada, N.; Yamazaki, H.; Kato, Y.; Mukai, T.; Toguchi, H.; Odomi, M.; Ogawara, K.; Higaki, K.; Kimura, T., Optimization of suppository preparation containing sodium laurate and taurine that can safely improve rectal absorption of rebamipide. Biol. Pharm. Bull., 2006, 29(2), 330-335.
135. Miyake, M.; Minami, T.; Toguchi, H.; Odomi, M.; Ogawara, K.-I.; Higaki, K.; Kimura, T., Importance of bile acids for novel oral absorption system containing polyamines to improve intestinal absorption. J. Controlled Release, 2006, 115(2), 130-133.
136. Mukaizawa, F.; Taniguchi, K.; Miyake, M.; Ogawara, K.-i.; Odomi, M.; Higaki, K.; Kimura, T., Novel oral absorption system containing polyamines and bile salts enhances drug transport via both transcellular and paracellular pathways across Caco-2 cell monolayers. Int. J. Pharm., 2009, 367(1-2), 103-108.
137. Cheng, Y.; Xu, Z.; Ma, M.; Xu, T., Dendrimers as drug carriers: Applications in different routes of drug administration. J. Pharm. Sci., 2008, 97(1), 123-143.
138. Minko, T., Soluble polymer conjugates for drug delivery. Drug Discov. Today: Technol., 2005, 2, 15-20.
139. Trapani, A.; Garcia-Fuentes, M.; Alonso, M.J., Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan. Nanotechnology, 2008, 19(18).
140. Cheng, Y.; Xu, T., The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of noncovalently or covalently attached drugs. Eur. J. Med. Chem., 2008, 43(11), 2291-2297.
141. Gillies, E.R.; Frechet, J.M.J., Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today, 2005, 10(1), 35-43.
142. Svenson, S., Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharmaceut. Biopharmaceut., 2009, 71(3), 445-462.
143. Chapman, T.M.; Hillyer, G.L.; Mahan, E.J.; Shaffer, K.A., Hydraamphiphiles-novel linear dendritic block-copolymer surfactants. J. Am. Chem. Soc., 1994, 116(24), 11195-11196.
144. Kaminskas, L.M.; Wu, Z.; Barlow, N.; Krippner, G.Y.; Boyd, B.J.; Porter, C.J.H., Partly-PEGylated Poly-L-lysine Dendrimers Have Reduced Plasma Stability and Circulation Times Compared With Fully PEGylated Dendrimers. J. Pharm. Sci., 2009, 98(10), 3871-3875.
145. Al-Jamal, K.T.; Sakthivel, T.; Florence, A.T., Dendrisomes: Vesicular structures derived from a cationic lipidic dendron. J. Pharm. Sci., 2005, 94(1), 102-113.
146. Ross, B.P.; Toth, I., Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr. Drug Delivery, 2005, 2(3), 277-287.
147. Al-Jamal, K.T.; Sakthivel, T.; Florence, A.T., Dendrimer-heparin complexation. J. Pharm. Pharmacol., 2003, 55(Supplement).
148. Ribeiro, S.J.; Rijpkema, S.G.; Durrani, Z.; Florence, A.T., A Study of PA DNA/Dendron Nanoparticles for Genetic Immunisation Against Anthrax. The Open Vaccine Journal, 2008, 1, 38-44.
149. Nagabhushan, T.L.; Miller, G.H.; Weinstein, M.J., Structure-Activity Relationships in Aminoglycoside-Aminocyclitol Antibiotics. The Aminoglycosides: Microbiology, Clinical Use, and Toxicology; Marcel Dekker: New York, 3-27, 1982.
150. Perry, C.M.; Noble, S., Didanosine-An updated review of its use in HIV infection. Drugs, 1999, 58(6), 1099-1135.
151. Artursson, P.; Palm, K.; Luthman, K., Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Delivery Rev., 2001, 46(1-3), 27-43.
152. Violette, A.; Cortes, D.A.F.; Bergeon, J.A.; Falconer, R.A.; Toth, I., Optimized LC-MS/MS quantification method for the detection of piperacillin and application to the development of charged liposaccharides as oral penetration enhancers. Int. J. Pharm., 2008, 351(1-2), 152-157.
153. Bergeon, J.A.; Ziora, Z.M.; Abdelrahim, A.S.; Pernevi, N.U.; Moss, A.R.; Toth, I., In Vitro and In Vivo Evaluation of Positively Charged Liposaccharide Derivatives as Oral Absorption Enhancers for the Delivery of Anionic Drugs. J. Pharm. Sci., 2010, 99(5), 2333-2342.
154. Rege, B.D.; Yu, L.X.; Husain, A.S.; Polli, J.E., Effect of common excipients on Caco-2 transport of low-permeability drugs. J. Pharm. Sci., 2001, 90(11), 1776-1786.
155. Leonard, T.W.; Lynch, J.; McKenna, M.J.; Brayden, D.J., Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin. Drug Deliv., 2006, 3(5), 685-692.
156. Simovic, S.; Heard, P.; Hui, H.; Song, Y.; Peddie, F.; Davey, A.K.; Lewis, A.; Rades, T.; Prestidge, C.A., Dry Hybrid Lipid-Silica Microcapsules Engineered from Submicron Lipid Droplets and Nanoparticles as a Novel Delivery System for Poorly Soluble Drugs. Mol. Pharm., 2009, 6(3), 861-872.
157. Simerska, P.; Moyle, P.M.; Toth, I., Modern Lipid-, Carbohydrate-, and Peptide-Based Delivery Systems for Peptide, Vaccine, and Gene Products. Med. Res. Rev., 2011, 31(4), 520-547.
158. Mrsny, R.J., Perspective: Oral drug delivery research in Europe. J. Control Release, 2012, http://dx.doi.org/10.1016/ j.jconrel.2012.01.017.
159. Pillay, V.; Hibbins, A.R.; Choonara, Y.E.; du Toit, L.C.; Kumar, P.; Ndesendo, V.M.K., Orally administered therapeutic peptide delivery:enhanced absorption through the small intestine using permeation enhancers. Int. J. Pept. Res. Ther., 2012, doi: 10.1007/s10989-012-9299-7.
160. Bummer, P.M., Physical chemical considerations of lipid-based oral drug delivery-Solid lipid nanoparticles. Critical Reviews in Therapeutic Drug Carrier Systems, 2004, 21(1), 1-19.
161. Abuasal, B.S.; Lucas, C.; Peyton, B.; Alayoubi, A.; Nazzal, S.; Sylvester, P.W.; Kaddoumi, A., Enhancement of Intestinal Permeability Utilizing Solid Lipid Nanoparticles Increases γ-Tocotrienol Oral Bioavailability. Lipids, 2012, 47, 461-469.
162. Yap, S.P.; Yuen, K.H., Influence of lipolysis and droplet size on tocotrienol absortion from self-emulsifying formulations. Int. J. Pharm., 2004, 281(1-2), 67-78.
163. Hong, J.Y.; Kim, J.K.; Song, Y.K.; Park, J.S.; Kim, C.K., A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J. Controlled Release, 2006, 110(2), 332-338.
164. Zhang, Q.; He, N.; Zhang, L.; Zhu, F.; Chen, Q.; Qin, Y.; Zhang, Z.; Zhang, Q.; Wang, S.; He, Q., The in vitro and in vivo study on self-nanoemulsifying drug delivery system (SNEDDS) based on insulin-phospholipid complex. J. Biomed. Nanotechnol., 2012, 8, 90-97.
165. Thomas, N.; Muellertz, A.; Graf, A.; Rades, T., Influence of lipid composition and drug load on the In Vitro performance of selfnanoemulsifying drug delivery systems. J. Pharm. Sci., 2012, 101, 1721-1731.
166. Thomas, N.; Holm, R.; Mullertz, A.; Rades, T., In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J. Controlled Release, 2012, 160, 25-32.
167. Ruenraroengsak, P.; Cook, J.M.; Florence, A.T., Nanosystem drug targeting: Facing up to complex realities. J. Controlled Release, 2010, 141(3), 265-276.
168. Florence, A.T., "Targeting" nanoparticles: The constraints of physical laws and physical barriers. J Control Release, 2012, http://dx.doi.org/10.1016/j.jconrel.2012.03.022.
169. Wening, K.; Breitkreutz, J., Oral drug delivery in personalized medicine: Unmet needs and novel approaches. Int. J. Pharm., 2011, 404(1-2), 1-9.
170. Florence, A.T.; Lee, V.H.L., Personalised medicines: More tailored drugs, more tailored delivery. Int. J. Pharm., 2011, 415(1-2), 29-33.